SEPTInvestingStart Free

GRCE 10-Q: SEC filing

Grace Therapeutics

Filed with the SEC on · accession 0001140361-26-043299

GRCE filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Grace Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing ongoing efforts to address the FDA's Complete Response Letter for its lead drug candidate GTx-104 and plans to resubmit an NDA.

For details, click here →How to read a 10-Q →

Key details

RegistrantGrace Therapeutics, Inc.
RegulatorU.S. Food and Drug Administration

✦ Ask GOAX AI about this filing — what it means for GRCE, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for GRCE?

Click here

Frequently asked questions

What did GRCE file with the SEC on Nov 12, 2026?

GRCE filed a 10-Q (SEC filing). Grace Therapeutics filed its quarterly 10-Q report for the period ended September 30, 2026, disclosing ongoing efforts to address the FDA's Complete Response Letter for its lead drug candidate GTx-104 and plans to resubmit an NDA.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other GRCE SEC filings

Get alerts when GRCE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
GRCE overviewGRCE analysisGRCE newsLatest SEC filings